Sign in
TCRR Stock Price, Chart, Stats & News
TCR2 Therapeutics Inc.
Save
58.11M
Market cap
–
Current P/E
–
Forward P/E
TCRR chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.17% |
ROA | -72.91% |
ROE | -71.90% |
D/E | 0.38x |
Interest coverage ratio | -2.61x |
TCRR valuation
P/E | – |
P/S | – |
P/B | 0.41x |
P/CF | -0.56x |
P/FCF | -0.50x |
P/OCF | -0.56x |
PEG | -0.00x |
EV multiple | -0.41x |
About
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma.
Similar securities
Based on sector and market capitalization
Report issue